New cocktail of drugs shows promise for nasopharyngeal cancer
NCT ID NCT05305131
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding two immunotherapy drugs (pembrolizumab and bevacizumab) to standard chemotherapy (gemcitabine and cisplatin) works better for advanced nasopharyngeal cancer. About 50 participants will be randomly assigned to receive either the standard chemo or the new four-drug combo. The main goal is to see if the new combo leads to a complete metabolic response on a PET scan at 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gemcitabine, cisplatin, pembrolizumab, and bevacizumab
What this could lead to
If successful, this combination could offer a more effective treatment for advanced nasopharyngeal cancer, potentially improving survival and reducing relapse.
What could go wrong
This is a small, early-phase trial (50 people). The added drugs may cause more side effects, and the results may not lead to a new standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National University Hospital
RECRUITINGSingapore, Singapore
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••